6th LifeCourse Immunisation Summit - 2021


The stark reality is that the ongoing COVID-19 pandemic has forced us to face the fact that we are now living in a new era, one that is impacting all aspects of our lives, including our healthcare priorities. Established vaccine barriers to increase vaccination rates have now shifted and new ones have emerged, we must come together to identify, assess and react to these new priorities urgently. The Healthcare Community and Policymakers must address the new and emerging challenges before they become insurmountable. By bringing together the key organisations, opinion leaders, associations, and policymakers EIP are constantly working on what needs to change and what activities need to happen to support the desired change.

  • The Summit is tasked with identifying and supporting interventions and actions to increase vaccination rates across the board.

  • The Working Groups are tasked with discussing and debating the latest changes, along with the latest surveillance data, and then putting forward strategies and campaigns to overcome the vaccine barriers identified.

  • The smaller Expert Groups (typically 3-5 experts) are tasked with identifying, proposing and implementing actions to increase vaccination rates in a particular disease or policy area open a specific barrier or question.

Participants are invited individual experts, organisations, policymakers, patient group representatives. View the program below.

DAY ONE - Thursday 2nd December 2021 (11:00-12:00 CET)



Updates from EU Commission, Vaccine Coalition, ECDC, and the World Health Organization (WHO)

DAY ONE - Thursday 2nd December 2021 (12:00-13:30 CET)



Life Course Vaccination Strategies and Health Systems Resilience and Preparedness

  Focus: Health System Resilience and Preparedness through lifecourse vaccinations have never been more important. The Summit Working Group will look at the practical strategies to establish the evidence that vaccination for all ages against all vaccine-preventable diseases. Working to close the vaccination gap between childhood and adult vaccines and establishing and maintaining the national budget for vaccines. The Working Group has been running since 2015 and has a renewed importance and relevance in the current climate where vaccine and health budgets are under increased pressure.  


  Discussion Point 1: Compulsory Vaccines for COVID fundamentally changes the approach for Vaccines Rollouts in the Future. Does obligatory vaccination against COVID for specific groups, such as healthcare professionals, pave the way for similar interventions for other vaccines (e.g influenza)?  
  Discussion Point 2: Promoting and protecting the lifecourse vaccine approach and vaccination investment prioritization in a post-pandemic world. How can we best secure vaccination investment prioritization in a post-pandemic world as a critical component of resilient healthcare systems and pandemic preparedness plans?  
  Discussion Point 3: Covid-19 has highlighted the critical value and role of adult vaccination. How can we to build on Covid-19 experience to reinforce adult vaccination infrastructures and move to a lifecourse immunization approach in EU countries?  
DAY ONE - Thursday 2nd December 2021 (14:00-15:30 CET)



COVID Vaccines and Vaccine Confidence - How New Vaccines have Changed Attitudes and Perceptions and the Influence on other Vaccination Uptake and Confidence

  Focus: Looking at the ever-important and overarching task of increasing vaccine confidence but within the COVID Era. In particular, it's essential to establish how COVID vaccination policies have affected trends, attitudes and trust among the three main social groups; the believers, the indifferent, and those against vaccines. The Working Group of key stakeholders, experts and association representatives aim to identify the changes in awareness, understanding across Europe. The Group are tasked with seizing the unique opportunity for vaccine confidence to be boosted across Europe in 2022 and beyond.  


  Discussion Point 1: It is essential to establish how COVID vaccination policies have affected trends, attitudes and trust among the three main social groups; the believers, the indifferent, and those against vaccines. How can we identify and react to changes in dynamics, shifts in each group, and strengthen our policy responses?  
  Discussion Point 2: Societies and governments are putting a lot of pressure on people who are not vaccinated against COVID with their refusal to get vaccinated considered openly as anti-social and irresponsible behaviour. Will this change offer an opportunity to establish all vaccinations as socially responsible behaviour and duty to ourselves, our families, our friends and the broader societies? What are the wider implications of this approach on Vaccine Confidence?  
DAY ONE - Thursday 2nd December 2021 (16:00 -18:00 CET)



Meningococcal Vaccinations Against all Strains

  Focus: The Meningitis Working Group is now in its 6th year and its work is more important than ever. Tasked with countering any potential shift in Healthcare Professionals and Decision Makers’ priorities regarding the continued rollout and inclusion of meningitis vaccination for all strains. The Working Group aim to provide guidance on how the medical communities and the policymakers could navigate through these times to avoid a meningococcal time-bomb.  


  Discussion Point 1: With the Meningococcal Infections so low due to lockdowns, social distancing and schools and universities being closed, public interest has shifted from Meningitis and awareness and urgency to vaccinate has decreased . With most schools and universities now opening for the next academic year, how can we increase awareness and bring attention on the importance of Meningococcal Vaccinations once again? How do we secure increase uptake in adolescents and young adults in the aftermath of Covid-19 disruptions?  
  Discussion Point 2: We need to expand access to broader protection for all EU citizens and the Extension of Meningococcal Vaccination Programmes across Europe remains a priority, yet COVID has reduced the policy momentum. How can we establish the importance of protecting against meningococcal strains to all types and populations (ie children, adolescents, young adults)?  
DAY ONE - Thursday 2nd December 2021 (16:00 -18:00 CET)



Establishing the Burden and Potential Preventive Impact of RSV Vaccine for All Young Children

  Focus: The Respiratory Syncytial Virus (RSV) Vaccines Working Group has been convened to review and advise on the best strategies for avoiding the unnecessary hospitalisation of under 5s by the use of RSV vaccinations across Europe. Looking at the healthcare burden of hospitalisation in the first instance. This new area has the potential to significantly cut the number of hospitalisations per year (estimated to be 30,000 in the UK alone), but we must decide on the most successful strategy to establish RSV vaccinations in vaccine schedules over the coming years.  


  Discussion Point 1: We are currently missing and underreporting respiratory viral infections in infants and children. Do we know the real burden on our healthcare systems in Europe and is improved surveillance needed? What is the hidden burden of Respiratory Syncytial Virus (RSV) in Europe?  
  Discussion Point 2: We must take Respiratory Syncytial Virus (RSV) infections seriously when planning an holistic pneumonia-fighting strategy to protect all against all pneumonia causing infections. How should we better communicate the RSV burden, and the need to protect all infants, to policymakers?  
DAY TWO - Friday 3rd December 2021 (09:00 -11:00 CET)



Influenza Vaccinations as a Priority in the COVID-19 Era

  Focus: The Influenza Working Group Meeting, now in its 6th year, has the aim of increasing seasonal influenza vaccine above the target 75% in all countries across Europe, but crucially long-term. Influenza vaccination rates have been boosted in 2020/21 due to the need to avoid influenza caused hospitalisation in parallel to COVID-19 admissions. However, the very real fear is that influenza vaccination rates will fall back to even lower rates than pre-COVID levels in future years.  


  Discussion Point 1: Influenza infection is often perceived as a minor threat by healthy adults except for the risk groups and elderly people. With COVID being a priority among all, how can we better communicate and establish the need for an equally strong take-up and influenza vaccine each flu season?  
  Discussion Point 2: COVID Vaccine Efficacy and Expectation on Other Vaccines. With the public now being used to efficacy rates of 90% of the new mRNA vaccines, could the currently lower efficacy of existing vaccines affect public trust and vaccination coverage against influenza? What can we do to counter this perception? How can we make the most of existing flu vaccines to provide the best protection for the elderly population while continuing the development of innovative vaccines?  
  Discussion Point 3: Aligned COVID and Influenza Vaccination Strategies are more important than ever. How can we sustain political momentum and secure strong long-term influenza campaign implementation with concomitant Covid vaccination programmes?  
DAY TWO - Friday 3rd December 2021 (09:00 -11:00 CET)



Expanding Coverage Against Pneumococcal Infections

  Focus: The Pneumococcal Working Group has been convened to review and advise whether Pneumococcal Vaccinations should be expanded to cover all ages and not only children and high-risk groups as part of a strategy to eliminate other threats of infectious diseases. Such a move would allow stretched health systems dealing with the COVID-19 pandemic, and its aftermath, to redirect and relocate resources. Looking at if wide-scale Pneumococcal vaccinations is the right move at this current time.  


  Discussion Point 1: We need to expand “pneumonia-fighting” vaccines* during the COVID-19 pandemic and beyond to not only reduce the risk of increases in child pneumonia deaths from non-SARS-CoV-2 causes during the pandemic but to reduce the risk of adult co-infection with bacterial pneumonia and SARS-CoV-2, taking the pressure off already stressed health systems. How can we best established the burden and communicate this to policymakers?  
  Discussion Point 2: Policy Makers have the opportunity to introduce a holistic pneumonia-fighting policy and national Pneumonia Control Strategies by utilising COVID Vaccination, existing and emerging pneumococcal vaccines as they become available and prioritizing access to the most vulnerable populations (e.g., children, the elderly, healthcare workers etc). What is the optimum approach for each vaccine and in each country setting?  




DAY TWO - Friday 3rd December 2021 (11:30-13:00 CET)
Interventions to increase vaccination uptake among healthcare professionals


DAY TWO - Friday 3rd December 2021 (11:30-13:00 CET)
Is the vaccination of children against COVID-19 necessary to achieve community immunity?


DAY TWO - Friday 3rd December 2021 (13:30-15:00 CET)
How to educate healthcare professionals across all specialties on the different vaccines technologies and their pros and cons.


DAY TWO - Friday 3rd December 2021 (13:30-15:00 CET)
Strategies to increase vaccinations of pregnant women


DAY TWO - Friday 3rd December 2021 (16:30-18:00 CET)
How to reach out and communicate with adolescents to increase Meningococcal Vaccination uptake?


DAY TWO - Friday 3rd December 2021 (16:30-18:00 CET)
Strategies to increase vaccination coverage of patients with chronic conditions